)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sonnet BioTherapeutics
Sonnet BioTherapeutics (SONN) investor relations material
Sonnet BioTherapeutics has been acquired
Sonnet BioTherapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary16 Dec, 2025
Executive summary
Clinical-stage biotech focused on oncology, leveraging proprietary FHAB technology for targeted biologic medicines, with a pipeline led by SON-1010 (IL-12-FHAB) in solid tumors and SON-080 (IL-6) for neuropathy indications.
Completed a business combination with Hyperliquid Strategies Inc. and Rorschach I LLC in December 2025, becoming a wholly owned subsidiary of HSI.
Ongoing collaborations with Roche (atezolizumab combo) and Alkem (SON-080 in India); New Life Therapeutics partnership for SON-080 in ASEAN region is being renegotiated.
Financial highlights
Fiscal year ended September 30, 2025: Collaboration revenue of $1.0 million (Alkem Agreement), up from $18,626 in 2024.
Net loss of $16.0 million, compared to $7.4 million in the prior year, driven by increased R&D and G&A expenses.
Research and development expenses rose to $8.4 million (from $5.7 million), mainly due to higher clinical trial costs.
General and administrative expenses increased to $8.5 million (from $6.1 million), reflecting higher professional fees and transaction costs.
Cash and cash equivalents at year-end: $5.1 million; stockholders' equity: $10.8 million.
Cash used in operations: $12.8 million; net cash provided by financing activities: $26.0 million.
Outlook and guidance
Cash runway projected into February 2026; substantial additional financing required to fund operations and clinical development.
Focus on advancing SON-1010 in solid tumors and SON-080 in neuropathy, with ongoing cost management and prioritization of high-potential assets.
Plans to seek further equity, debt, or partnership funding; potential asset sales or operational reductions if capital is not secured.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sonnet BioTherapeutics
- Biotech firm offers 5.77M shares via warrants to fund R&D amid ongoing financial risks.SONN
Registration Filing - Shareholders to vote on Sonnet-Rorschach merger, creating Pubco with a HYPE token treasury focus.SONNProxy Filing
- Key votes include director elections, a large equity issuance, and a reverse stock split to retain Nasdaq listing.SONNProxy Filing
- Virtual meeting to elect directors, approve pay, set say-on-pay frequency, and ratify auditor.SONNProxy Filing
- Key votes include director elections, equity issuance, reverse split, and auditor ratification.SONNProxy Filing
- Biotech raises $4.4M via stock and warrants to fund R&D amid ongoing losses and cash constraints.SONNRegistration Filing
- Biotech seeks $4.4M via IPO to fund R&D amid ongoing losses and a limited cash runway.SONNRegistration Filing
- Biotech firm offers shares and warrants for resale, targeting R&D funding amid financial risks.SONNRegistration Filing
- Up to 2,000,000 shares registered for resale under a $25M equity facility, with high dilution risk.SONNRegistration Filing
Sonnet BioTherapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sonnet BioTherapeutics Holdings Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development of innovative biologic drugs for cancer and other serious diseases. The company utilizes a proprietary platform to design fully human fusion proteins that enhance the therapeutic activity and delivery of cytokines. Sonnet’s pipeline targets various solid tumors and immunological conditions, with development efforts supported by preclinical and clinical research. The company is headquartered in Princeton, New Jersey, and its shares are listed on the NASDAQ.